13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
24 檔
49.4%
During the Q2 2025 filing period, BML Capital Management, LLC (CIK: 0001616824) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $175.7M across 24 reported positions.
During Q2 2025, BML Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 20.73% | -5.98% | — | |
| 2 | ✓ | Third Harmonic Bio Inc | Stock-Other | 15.71% | — | — | |
| 3 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 15.31% | +1.74% | — | |
| 4 | TIL | Instil Bio Inc | Stock-Other | 8.43% | -0.59% | +28.36% | |
| 5 | EPIEUR | Essa Pharma Inc | Stock-Other | 5.43% | — | — | |
| 6 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 5.25% | -4.54% | +2.07% | |
| 7 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 4.97% | — | +11.49% | |
| 8 | ✓ | Ikena Oncology Inc | Stock-Other | 4.09% | — | +8.60% | |
| 9 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 4.01% | -0.18% | +33.42% | |
| 10 | ALMS | Alumis Inc | Stock-Other | 2.75% | — | +2339.03% | |
| 11 | 2KZ0 | Kezar Life Sciences Inc | Stock-Other | 2.20% | -3.43% | EXIT | |
| 12 | ✓ | Lava Therapeutics NV | Stock-Other | 1.97% | — | +0.51% | |
| 13 | MIST | Milestone Pharmaceuticals In | Stock-Other | 1.67% | — | — | |
| 14 | ✓ | Elevation Oncology Inc | Stock-Other | 1.64% | — | -0.01% | |
| 15 | CNTB | Connect Biopharma Holdings Limited | Stock-Other | 1.35% | — | -12.98% | |
| 16 | TSLA | Tesla Inc | Stock-Consumer Disc | 1.25% | +0.15% | NEW | |
| 17 | ASTC | Astrotech CORP | Stock-Other | 0.96% | — | — | |
| 18 | ✓ | Athira Pharma Inc | Stock-Other | 0.74% | — | +0.94% | |
| 19 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.46% | — | -3.25% | |
| 20 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.36% | — | — | |
| 21 | ✓ | Turnstone Biologics CORP | Stock-Other | 0.30% | — | — | |
| 22 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.23% | — | — | |
| 23 | ✓ | Hillevax Inc | Stock-Other | 0.14% | — | +342.74% | |
| 24 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 24 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AVIR, THIRD HARMONIC BIO INC, ACRS) accounted for 49.4% of total reported equity market value during Q2 2025.
During Q2 2025, BML Capital Management, LLC's top holdings by market value included AVIR (20.7%)、THIRD HARMONIC BIO INC (15.7%)、ACRS (15.3%). The largest single position, AVIR, represented 20.7% of total portfolio value.
In Q2 2025, BML Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.